Fluorescent In Situ Hybridization Probe Market to Grow with a CAGR of 7.29% through 2028
Advancements in genomic research, and the critical
role of FISH probes in cancer diagnostics is expected to drive the Global Fluorescent
In Situ Hybridization Probe Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “Fluorescent
In Situ Hybridization Probe Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Fluorescent
In Situ Hybridization Probe Market stood at USD 859.62 million in 2022 and is
anticipated to grow with a CAGR of 6.50% in the forecast period, 2024-2028.
This can be attributed to emerging markets. While North America and Europe have
traditionally been key markets for FISH probes, the market is expanding in
emerging regions, particularly in Asia-Pacific. Increasing investments in
healthcare infrastructure, research, and development activities in these
regions are driving market growth.
Moreover, collaboration between academia, industry,
and research consortia is fostering innovation in FISH technology. These
partnerships are driving the development of new probes, protocols, and
applications, accelerating the pace of discovery and commercialization.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Fluorescent In Situ Hybridization Probe Market.”
The market's expansion can be attributed to several
key factors. One of these factors is the rising demand for in vitro diagnostics
(IVD) in the diagnosis of various chronic diseases. This is facilitated by the
technique's high levels of reliability, speed, and sensitivity. Additionally,
over the years, diagnostic methods employing DNA probes have gained significant
acceptance in medical diagnostics for detecting diseases caused by bacteria or
pathogens. This is driven by the increasing need for effective and early
treatment. The COVID-19 pandemic has also had a notable impact on the market,
with a growing number of research studies incorporating fluorescent in situ
hybridization (FISH). For example, in November 2022, an article in the PLOS One
Journal demonstrated the use of a FISH-based method to identify SARS-CoV-2 in
saliva samples, showcasing the versatility of FISH technology.
The market is expected to maintain a steady growth
rate over the forecast period, primarily due to the increasing global
prevalence of cancer and genetic disorders. The detection of new areas for
diagnostic applications, the rapid automation of diagnostic tests, and
investments in pharmacogenomics and pharmaceutical research are driving this
growth.
The rising incidence of genetic disorders, such as
Acute Lymphoblastic Leukemia (ALL), is also poised to contribute to market
expansion. For example, in 2023, nearly 6,500 new cases of ALL were diagnosed
in the U.S., leading to 1,300 deaths, according to the American Cancer Society.
Cytogenetic techniques significantly aid in the detection of chromosomal
abnormalities related to cancer. The U.S. is expected to witness the diagnosis
of 1.9 million new cancer cases in 2023, as per the American Cancer Society
Cancer Statistics for 2023. Similarly, the Australian Institute of Health and
Welfare's 2021 report projected around 150,782 cancer cases in Australia in
2021.
Moreover, the ICMR 2021 Report highlighted an
anticipated increase in the number of cancer patients in India, expected to
rise from 26.7 million in 2021 to 29.8 million by 2025. The substantial global
burden of cancer underscores the effectiveness of FISH in disease diagnosis and
treatment planning, which further fuels growth in this specific segment.
Additionally, the market is benefiting from increasing research and development
efforts by key players to develop novel disease-specific biomarkers and
pipeline products awaiting regulatory approval. Growing public awareness,
coupled with increased healthcare expenditure and the development of innovative
probes, are expected to drive market growth..
The Global Fluorescent In Situ Hybridization Probe Market
is segmented into technology, type, application, end-use, regional
distribution, and company.
Based on its application, the largest share of revenue
in 2022 was held by the cancer diagnostics segment. FISH probes are
predominantly utilized in genetic disease research and cancer diagnostics. The
increasing global incidence of cancer, leading to a growing demand for precise,
swift, and reliable molecular diagnostic tests, is a significant driver of
market growth. Within cancer diagnostics, these probes are extensively employed
for detecting breast and lung cancer. Furthermore, the development of
innovative diagnostics using FISH technology is contributing to the expansion
of the market. For example, the UroVysion FISH test kit is utilized for
diagnosing urological cancers.
On the other hand, the utilization of FISH technology
in combination with a fluorescent microscope is gaining increasing preference
in cytogenetic analysis due to its distinct advantages, including exceptional
detection precision, heightened sensitivity, and extended experimental
duration. FISH has demonstrated remarkable effectiveness in identifying
abnormalities within the MET gene associated with non-small cell lung cancer,
as well as in detecting genes linked to breast cancer. These factors, combined
with the high sensitivity and efficient testing capabilities offered by FISH
probes, are expected to fuel growth in the cancer diagnostics application
segment.
Based on end-use, the clinical application segment was
the dominant force in the market in 2022, commanding a significant share of
revenue. This was primarily due to the widespread use of FISH probes in the
identification and diagnosis of genetic disorders, cancer, and infectious
diseases. Fluorescence in situ hybridization is a widely embraced technology
for detecting genetic abnormalities, and its applications span clinical
procedures, companion diagnostics, and research endeavors.
The technology's specificity, high sensitivity, and
rapid assay execution have established it as a crucial cytogenetic test,
offering substantial advantages in both research and diagnostic investigations
related to hematological malignancies and solid tumors. These probes are
instrumental in research studies, aiding in tasks such as gene mapping,
identifying genetic aberrations, and uncovering novel oncogenes in the realm of
cancer detection and treatment. Additionally, they play a vital role in
molecular-based testing, contributing to gene mapping and the discovery of new
oncogenes.
The influence of FISH extends to clinical and
microbiological detection approaches, largely owing to its remarkable
specificity and efficiency. As a result, it has become one of the most commonly
adopted techniques for clinical microbiological detection. The segment's growth
is driven by extensive research into genetic abnormalities associated with
diseases and the escalating prevalence of genomic anomalies and cancer.
Major companies operating in
Global Fluorescent In Situ Hybridization Probe Market are:
- Thermo Fisher Scientific Inc.
- PerkinElmer Health Sciences Inc
- Biodot Inc
- New Horizons Diagnostic Corp
- Merck KGaA
- Agilent Technologies, Inc.
- Abnova Corp.
- Genemed Biotechnologies Inc
- Hoffmann-La Roche Ltd
- Oxford Gene Technology Ltd
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The future of the Global Fluorescent In Situ
Hybridization (FISH) Probe Market is poised to be characterized by innovation,
customization, and increased accessibility. The field is rapidly evolving to
meet the expanding demands of genomics, diagnostics, and precision medicine.
From non-invasive prenatal testing to AI-assisted analysis and spatial
genomics, these trends are not only expected to fuel market growth but also
empower researchers and clinicians with advanced tools to unlock the mysteries
of the genome. As we move forward, the FISH Probe Market is set to play a
pivotal role in shaping the future of genetics and molecular biology,” said Mr.
Karan Chechi, Research Director with TechSci Research, a research-based
management consulting firm.
“Fluorescent In Situ Hybridization Probe Market
By Technology
(Q FISH, FLOW FISH, Others), By Type (DNA, RNA (mRNA, miRNA, Others)), By Application
(Cancer Research, Genetic Diseases, Others), By End-Use (Research, Clinical,
Companion Diagnostics), By Region, By
Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Fluorescent In Situ Hybridization Probe Market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Fluorescent In Situ Hybridization Probe
Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]
Website:
www.techsciresearch.com